{
    "clinical_study": {
        "@rank": "112588", 
        "arm_group": [
            {
                "arm_group_label": "A: phenprocoumon single dose", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "B: vemurafenib + phenprocoumon single dose", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This open-label, multicenter, parallel study will evaluate the effect of multiple doses of\n      vemurafenib on the pharmacokinetics of a single dose of phenprocoumon in patients with\n      BRAFV600 mutation-positive metastatic malignancies. Patients will be randomized to receive\n      either treatment A: a single oral dose of phenprocoumon 6 mg on Day 1 (Eligible patients\n      will have the option to continue treatment with vemurafenib as part of an extension study\n      (NCT01739764).), or treatment B: vemurafenib 960 mg orally twice daily on Days 1-29 plus a\n      single oral dose of phenprocoumon 6 mg on Day 22 (with the option to receive vemurafenib in\n      the extension study after completion of pharmacokinetic assessments)."
        }, 
        "brief_title": "A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Malignant Melanoma, Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Melanoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients,  18-70 years of age\n\n          -  Patients with either unresectable Stage IIIc or IV BRAFV600 mutation-positive\n             metastatic melanoma or other malignant BRAFV600 mutation-positive tumor type and who\n             have no acceptable standard treatment options\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2\n\n          -  Full recovery from any major surgery or significant traumatic injury at least 14 days\n             prior to the first dose of study treatment\n\n          -  Adequate hematologic and end organ function\n\n          -  Female patients of childbearing potential and male patients with female partners of\n             childbearing potential must agree to use 2 effective methods of contraception as\n             defined by protocol during the course of the study and for at least 6 months after\n             completion of study treatment\n\n        Exclusion Criteria:\n\n          -  Prior treatment with vemurafenib or other BRAF inhibitor within 42 days of Day 1\n\n          -  Prior anti-cancer therapy within 28 days (6 weeks for nitrosureas or mitocyn C, or 14\n             days for hormonal therapy or kinase inhibitors) before the first dose of study\n             treatment Day 1\n\n          -  Palliative radiotherapy within 2 weeks prior to first dose of study treatment Day 1\n\n          -  Experimental therapy within 4 weeks prior to first dose of study treatment Day 1\n\n          -  History of clinically significant cardiac or pulmonary dysfunction, including current\n             uncontrolled Grade >/=2 hypertension or unstable angina\n\n          -  Current Grade >/=2 dyspnea or hypoxia or need for oxygen supplementation\n\n          -  History of myocardial infarction within 6 months prior to first dose of study\n             treatment\n\n          -  Active central nervous system lesions (i.e. patients with radiographically unstable,\n             symptomatic lesions)\n\n          -  History of bleeding or coagulation disorders\n\n          -  Allergy or hypersensitivity to vemurafenib or phenprocoumon formulations\n\n          -  History of malabsorption or other condition that would interfere with the enteral\n             absorption of study treatment\n\n          -  History of clinically significant liver disease (including cirrhosis), current\n             alcohol abuse, or active hepatitis B or hepatitis C virus infection\n\n          -  Human immunodeficiency virus (HIV) infection requiring antiretroviral treatment, or\n             AIDS-related illness\n\n          -  Pregnant or lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01849666", 
            "org_study_id": "GO28398", 
            "secondary_id": "2012-003707-35"
        }, 
        "intervention": [
            {
                "arm_group_label": "B: vemurafenib + phenprocoumon single dose", 
                "description": "960 mg bid orally", 
                "intervention_name": "vemurafenib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "A: phenprocoumon single dose", 
                "description": "6 mg oral single dose", 
                "intervention_name": "phenprocoumon", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Phenprocoumon"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium", 
                        "zip": "1000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium", 
                        "zip": "2650"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium", 
                        "zip": "9000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilrijk", 
                        "country": "Belgium", 
                        "zip": "2610"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland", 
                        "zip": "00180"
                    }
                }, 
                "status": "Terminated"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "zip": "69120"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany", 
                        "zip": "55101"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1066 CX"
                    }
                }, 
                "status": "Terminated"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands", 
                        "zip": "6229 HX"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3584 CX"
                    }
                }, 
                "status": "Terminated"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "L'Hospitalet de Llobregat", 
                        "country": "Spain", 
                        "state": "Barcelona", 
                        "zip": "08908"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pamplona", 
                        "country": "Spain", 
                        "state": "Navarra", 
                        "zip": "31008"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28040"
                    }
                }, 
                "status": "Terminated"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28031"
                    }
                }, 
                "status": "Terminated"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28046"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Finland", 
                "Germany", 
                "Netherlands", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A PHASE I, OPEN-LABEL, MULTICENTER, RANDOMINZED, PARALELL STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF PHENPROCOUMON IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: GO28398 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics of single-dose phenprocoumon under conditions of vemurafenib steady-state exposure: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 168 hours post-dose"
            }, 
            {
                "measure": "Pharmacokinetics of single-dose phenprocoumon under conditions of vemurafenib steady-state exposure: Maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 168 hours post-dose"
            }, 
            {
                "measure": "Pharmacokinetics of single-dose phenprocoumon under conditions of vemurafenib steady-state exposure: Time to maximum plasma concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 168 hours post-dose"
            }, 
            {
                "measure": "Pharmacokinetics of single-dose phenprocoumon under conditions of vemurafenib steady-state exposure: Terminal half-life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 168 hours post-dose"
            }, 
            {
                "measure": "Pharmacokinetics of single-dose phenprocoumon under conditions of vemurafenib steady-state exposure: Apparent clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 168 hours post-dose"
            }
        ], 
        "removed_countries": {
            "country": "Brazil"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01849666"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety: Incidence, nature and severity of adverse events (AEs) and serious AEs, graded according to NCI CTCAE Version 4.0", 
            "safety_issue": "No", 
            "time_frame": "approximately 1.5 years"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}